Incidence and prognostic factors in patents (Pts) with mutant braf (mbraf) metastatic colorectal cancer (MCRC) in Russia Научная публикация
| Журнал |
Meditsinskiy Sovet
ISSN: 2079-701X |
||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Вых. Данные | Год: 2021, Номер: 4S, Страницы: 52-63 Страниц : 12 DOI: 10.21518/2079-701X-2021-4S-52-63 | ||||||||||||||||||||||||
| Ключевые слова | Colorectal cancer; Epidemiology; Free progression survival; MBRAF; Overall survival; Prognosis | ||||||||||||||||||||||||
| Авторы |
|
||||||||||||||||||||||||
| Организации |
|
Реферат:
Introduction. mBRAF mCRC has the aggressive phenotype. The incidence of such mutation in Europe and the USA is around 8–14%, in Asian countries – 4–8%. The purpose of this population-based study was to determine the incidence and identifying prognostic factors in pts with mBRAF mCRC in Russia. Materials and methods. A multicenter retrospective analysis of clinical data and treatment results of pts with mBRAF mCRC was performed. The main method for determining mutations was a PCR. The main efficacy endpoint was progression free survival (PFS) at the 1 st line. Multivariate analysis was performed using Cox regression model. Results and discussion. 437 out of 8648 pts (5.17%) with a known mutational status had mBRAF (V600). Clinical data were collected from 131/437 (30%): the right-sided primary tumor – in 58,6%, left-sided – in 19%, rectum – in 21,4%. ORR in pts with mBRAF was 31%, median PFS was 6 months. We didn’t revealed any differences between FOLFOXIRI and doublets (XELOX/ FOLFOX or XELIRI/FOLFIRI) in terms of PFS (HR 0.9, 95% CI 0.49–1.52, р = 0.6) and OS (HR 1.5, 95% CI 0.61–4.1, р = 0.35) in pts with mBRAF. Conclusions. The incidence of mBRAF gene in the population of pts with mCRC in the Russia is low and we found a high incidence of localization of the primary tumor in the rectum. We didn’t reveal any differences between the usual duplets and standard regimen for such mutation-FOLFOXIRI in term of 1 st line PFS. © 2021, Remedium Group Ltd. All rights reserved.
Библиографическая ссылка:
Fedyanin M.Y.
, Ehlsnukaeva K.K.-M.
, Demidova I.A.
, Stroyakovskiy D.L.
, Shelygin Y.A.
, Tsukanov A.S.
, Panina M.V.
, Shubin V.P.
, Moiseenko F.V.
, Karpenko E.Y.
, Bolotina L.V.
, Kudryavtseva A.V.
, Filipenko M.L.
, Oskorbin I.P.
, Vladimirova L.Y.
, Timoshkina N.N.
, Kit O.I.
, Stroganova A.M.
, Dranko S.L.
, Senderovich A.I.
, Tryakin A.A.
, Tjulandin S.A.
Incidence and prognostic factors in patents (Pts) with mutant braf (mbraf) metastatic colorectal cancer (MCRC) in Russia
Meditsinskiy Sovet. 2021. N4S. P.52-63. DOI: 10.21518/2079-701X-2021-4S-52-63 Scopus OpenAlex
Incidence and prognostic factors in patents (Pts) with mutant braf (mbraf) metastatic colorectal cancer (MCRC) in Russia
Meditsinskiy Sovet. 2021. N4S. P.52-63. DOI: 10.21518/2079-701X-2021-4S-52-63 Scopus OpenAlex
Оригинальная:
Федянин М.Ю.
, Эльснукаева Х.М.
, Демидова И.А.
, Строяковский Д.Л.
, Шелыгин Ю.А.
, Цуканов А.С.
, Панина М.В.
, Шубин В.П.
, Моисеенко Ф.В.
, Карпенко Е.Ю.
, Болотина Л.В.
, Кудрявцева А.В.
, Филипенко М.Л.
, Оскорбин И.П.
, Владимирова Л.Ю.
, Тимошкина Н.Н.
, Кит О.И.
, Строганова А.М.
, Дранко С.Л.
, Сендерович А.И.
, Трякин А.А.
, Тюляндин С.А.
Колоректальный рак с мутацией в гене BRAF в Российской Федерации: эпидемиология и клинические особенности. результаты многоцентрового исследования
Медицинский совет. 2021. Т.4. С.52-63. РИНЦ
Колоректальный рак с мутацией в гене BRAF в Российской Федерации: эпидемиология и клинические особенности. результаты многоцентрового исследования
Медицинский совет. 2021. Т.4. С.52-63. РИНЦ
Идентификаторы БД:
| Scopus: | 2-s2.0-85118970976 |
| OpenAlex: | W4361868929 |